Study on Chemoimmunotherapy for Treating Men with Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Inclusion Criteria

• Have neuroendocrine-like prostate cancer based on specific medical criteria or aggressive prostate cancer with certain risk features.
• Must provide tumor samples for review and study.
• Have progressive metastatic castration-resistant prostate cancer (CRPC) as determined by specific medical criteria.
• Have low testosterone levels or ongoing androgen deprivation therapy (ADT).
• Have a performance status score of 70 or higher, indicating the ability to carry out daily activities.
• Meet acceptable laboratory test results within 14 days before starting treatment.
• Be over 18 years old.
• Agree to use effective contraception if they have a partner who can become pregnant.
• Be willing to provide written informed consent and authorization for the release of personal health information.
• Have a life expectancy of more than three months as determined by the treating physician.

Exclusion Criteria

• Have received certain prostate cancer treatments within two weeks before starting the study.
• Have received prior treatment with specific immune checkpoint inhibitors or other investigational drugs within four weeks before starting the study.
• Have had more than one chemotherapy regimen for metastatic CRPC.
• Have received radiation therapy within two weeks before starting the study and have not recovered from related side effects.
• Have received a live vaccine within 30 days before starting the study.
• Are currently participating in another clinical trial or have used an investigational device within four weeks before starting the study.
• Have a diagnosis of immunodeficiency or are receiving high-dose steroid therapy or other immunosuppressive treatments.
• Have a history of another cancer unless treated and in remission for at least two years.
• Have untreated or unstable brain metastases or carcinomatous meningitis.
• Have active autoimmune disease requiring treatment in the past two years.
• Have a history of lung inflammation requiring steroids or current lung inflammation.
• Have an active infection requiring treatment.
• Have uncontrolled HIV infection or active hepatitis B or C infection.
• Have active tuberculosis.
• Have significant nerve damage (Grade 2 or higher neuropathy).
• Have any condition or treatment that might interfere with the study or is not in the participant's best interest.
• Have psychiatric or substance abuse disorders that would interfere with study participation.
• Have had an organ transplant.